TG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%

TG Therapeutics, Inc. (NASDAQ:TGTX) shares traded up 4.8% during mid-day trading on Thursday . The stock traded as high as $14.63 and last traded at $14.48. 1,638,056 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 4,168,954 shares. The stock had previously closed at $13.82.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research report on Thursday. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. Finally, B. Riley raised their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.00.

TG Therapeutics Trading Up 1.2 %

The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of 712.86 and a beta of 2.30. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The business’s 50-day simple moving average is $15.14 and its two-hundred day simple moving average is $13.87.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. The company had revenue of $43.97 million for the quarter, compared to analyst estimates of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same quarter last year, the firm posted ($0.39) earnings per share. On average, research analysts anticipate that TG Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of TG Therapeutics by 16.9% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company’s stock valued at $2,811,000 after acquiring an additional 26,761 shares during the period. Los Angeles Capital Management LLC boosted its holdings in shares of TG Therapeutics by 55.8% during the first quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 27,437 shares during the period. Vanguard Group Inc. boosted its holdings in shares of TG Therapeutics by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock valued at $233,500,000 after acquiring an additional 199,770 shares during the period. Wellington Management Group LLP boosted its holdings in shares of TG Therapeutics by 1.4% during the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock valued at $53,627,000 after acquiring an additional 43,290 shares during the period. Finally, Eventide Asset Management LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at $7,506,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.